{"prompt": "['diagnosis (e.g., \"infusion-related reaction\", \"injection-related reaction\", \"injection-site', 'reaction\", \"infusion-site reaction\", \"anaphylactic reaction\") on the Adverse Event eCRF. If', 'possible, avoid ambiguous terms such as \"systemic reaction.\" Associated signs and', 'symptoms should be recorded on the dedicated Infusion-Related Reaction eCRF or', 'Injection-Related Reaction eCRF. If a patient experiences both a local and systemic reaction', 'to the same dose of study drug, each reaction should be recorded separately on the Adverse', 'Event eCRF, with signs and symptoms also recorded separately on the dedicated Infusion-', 'Related Reaction eCRF or Injection-Related Reaction eCRF.', 'See Table 2 for the reporting conventions for infusion-related reactions, injection-related', 'reactions, nd-injection-site reactions and infusion-site reactions.', 'Table 2', 'Reporting Conventions for Administration-Related Reactions', 'Term to Be Used on', 'Adverse Event', 'Symptoms to Be Entered on', 'Adverse Event eCRF Form', 'eCRF Form', 'Systemic Infusion Reaction', '\"Infusion-related reaction\"', 'Infusion-related reaction', 'Systemic Injection Reaction', '\"Injection-related reaction\"', 'Injection-related reaction', 'Local Injection Reaction', '\"Injection-site reaction\"', 'Injection-site reaction', 'Local Infusion Reaction', '\"Infusion-site reaction\"', '\"Infusion-site reaction\"', '5.3', 'METHODS AND TIMING FOR CAPTURING AND ASSESSING', 'SAFETY PARAMETERS', 'The investigator is responsible for ensuring that all AEs (see Section 5.2.1 for definition) are', 'recorded on the Adverse Event eCRF and reported to the Sponsor in accordance with', 'instructions provided in this section and in Section 5.4-5.6.', 'For each AE recorded on the Adverse Event eCRF, the investigator will make an', 'assessment of seriousness (see Section 5.2.2 for seriousness criteria), severity (see Section', '5.3.3), and causality (see Section 5.3.4).', '5.3.1', 'Adverse Event Reporting Period', 'Investigators will seek information on AEs at each patient contact. All AEs, whether reported', \"by the patient or noted by study personnel, will be recorded in the patient's medical record\", 'and on the Adverse Event eCRF.', 'After informed consent has been obtained but prior to initiation of study drug, only SAEs', 'caused by a protocol-mandated intervention (e.g., invasive procedures such as biopsies,', 'discontinuation of medications) should be reported (see Section 5.4.2 for instructions for', 'reporting SAEs).', 'After initiation of study treatment, all AEs regardless of relationship to study drug will be', 'reported until 28 days after the last dose of study drug. Between 28 days and 7 months from', 'the last study dose the following AEs will be reported:', 'study drug-related SAEs', 'AEs of special interest, heart failure, pregnancies, non-breast-related second primary', 'malignancies and deaths, irrespective of causal relationship', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '69 / Protocol MO40628, Version 42']['Instructions for reporting AEs that occur after the adverse event reporting period are', 'provided in Section 5.6.', '5.3.2', 'Eliciting Adverse Event Information', 'A consistent methodology of non-directive questioning should be adopted for eliciting AE', 'information at all patient evaluation timepoints. Examples of non-directive questions include', 'the following:', '\"How have you felt since your last clinic visit?\"', '\"Have you had any new or changed health problems since you were last here?\\'', '5.3.3', 'Assessment of Severity of Adverse Events', 'The AE severity grading scale for the NCI CTCAE v4.0 will be used for assessing AE', 'severity. Table 3 will be used for assessing severity for AEs that are not specifically listed in', 'the NCI CTCAE.', 'Table 3', 'Adverse Event Severity Grading Scale for Events Not Specifically Listed', 'in NCI CTCAE', 'Grade', 'Severity', '1', 'Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or', 'intervention not indicated', '2', 'Moderate; minimal, local, or non-invasive intervention indicated; or limiting', 'age-appropriate instrumental activities of daily living [a]', '3', 'Severe or medically significant, but not immediately life-threatening; hospitalization', 'or', 'prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily', 'living [b,c]', '4', 'Life-threatening consequences or urgent intervention indicated [d]', '5', 'Death related to adverse event [d]', 'NCI CTCAE = National Cancer Institute Common Terminology Criteria for Adverse Events.', 'Note: Based on the most recent version of NCI CTCAE v4.0, which can be found at:', 'http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm', 'a.', 'Instrumental activities of daily living refer to preparing meals, shopping for groceries or', 'clothes, using the telephone, managing money, etc.', 'b. Examples of self-care activities of daily living include bathing, dressing and undressing,', 'feeding oneself, using the toilet, and taking medications, as performed by patients who are', 'not bedridden.', 'C.', 'If an event is assessed as a \"significant medical event,\" it must be reported as an SAE (see', 'Section 5.4.2 for reporting instructions), per the definition of an SAE in Section 5.2.2.', 'd.', 'Grade 4 and 5 events must be reported as SAEs (see Section 5.4.2 for reporting', 'instructions), per the definition of an SAE in Section 5.2.2.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '70 / Protocol MO40628, Version 42']\n\n###\n\n", "completion": "END"}